anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An extended wear electrocardiography patch is provided. A flexible backing is formed of an elongated strip of stretchable material. An electrocardiographic electrode is affixed to and conductively exposed on a contact surface of each end of the elongated strip. A flexible circuit is affixed on each end of the elongated strip. A non-conductive receptacle is adhered on one of the ends of the elongated strip on a surface opposite the contact surface and removably receives an electrocardiography monitor operable to obtain electrocardiographic signals. A physiological sensor is provided with the electrocardiography monitor or on the flexible backing. Memory is provided on the flexible backing and is programmed with a sampling rate to instruct the physiological sensor to obtain readings of physiological data. A battery is positioned on one end of the flexible backing to provide power to one or more of the physiological sensors and the electrocardiography monitor.
induced-pluripotent stem cell (iPSC)-derived neurospheroid (NSPH) models are an emerging in vitro toolkit to study the influence of inflammatory triggers on neurodegeneration and repair in a 3D neural environment. In contrast to their human counterpart, the absence of murine iPSC-derived NSPHs for profound characterisation and validation studies is a major experimental research gap, even though they offer the only possibility to truly compare or validate in vitro NSPH responses with in vivo brain responses. To contribute to these developments, we here describe the generation and characterisation of 5-week-old CX3CR1eGFP+/- CCR2RFP+/- murine (m)iPSC-derived bi-partite (neurons + astrocytes) and tri-partite (neurons + astrocytes + microglia) NSPH models that can be subjected to cellular activation following pro-inflammatory stimulation. First, cytokine analysis demonstrates that both bi-partite and tri-partite NSPHs can be triggered to release IL6 and CXCL10 following three days of stimulation with, respectively, TNFα + IL1β + IFNγ and LPS + IFNγ. Additionally, immunocytochemical analysis for G3BP1 and PABPC1 revealed the development of stress granules in both bi-partite and tri-partite NSPHs after 3 days of stimulation. To further investigate the observed signs of inflammatory response and cellular stress, we performed an untargeted transcriptomic and proteomic analysis of bi- and tri-partite NSPHs under steady-state and inflammatory conditions. Here, using the combined differential gene and protein expression profiles between unstimulated and stimulated NSPHs, Ingenuity Pathway Analysis (IPA) confirms the activation of canonical pathways associated with inflammation and cellular stress in both bi-partite and tri-partite NSPHs. Moreover, our multi-omics analysis suggests a higher level of downstream inflammatory responses, impairment of homeostatic and developmental processes, as well as activation of cell death processes in stimulated tri-partite NSPHs compared to bi-partite NSPHs. Concluding, these results emphasise the advantages of including microglia in NSPH research to study inflammation-induced neurodegeneration in a 3D neural environment.
A method of altering skin tissues by application of light energy. Hair coloring is altered by introduction of melanin to the hair and hair follicle. Delivery of melanin is enhance by encapsulation in a liposome. Liposomes are specifically selected for the ability to bind to the tissues of the epidermis. Light energy is applied to release the melanin and assist binding to the targeted tissues. Light energy is preferably provided by one of several laser light sources. The light energy is matched to the absorption of the melanin to reduce absorption and damage to surrounding untargeted skin tissues.
Subjects meeting all Eligibility Criteria and providing Informed Consent will be enrolled in one of two sequential dosing groups (Group A and B). Subjects will be treated sequentially with a minimum of one month interval between surgeries for the first three subjects in each dosing cohort. The remaining subjects in the cohort will be treated with a minimum interval of at least one week between surgeries. There will be 9 subjects in each group. No control group is included. All patients will received unilateral lumbar spinal cord injections of CNS10-NPC-GDNF cells.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to use of spirituous tinctures in diseases associated with mineral metabolism disorder. Invention proposes spirituous tincture containing cedar nuts milled raw and alcohol in concentration 40-50% taken in the ratio raw : alcohol = (6-10): 100. Invention proposes also method of treatment and arresting articular and muscular pains using the above indicated tincture. EFFECT: good therapeutic effect, absence of relapses. 2 cl, 3 ex
Thromboembolic events in patients with chronic kidney disease are out of proportion to age matched controls occurring 2.34 times more frequently than in non-CKD patients (PMID 19561505). At the same time, patients with kidney disease are not offered the gold standard for pulmonary embolus diagnosis, i.e. CT angiography, for concern of acute dialysis to treat contrast-induced nephropathy. Ventilation perfusion scintigraphy (V/Q) is the preferred diagnostic test for patients with advanced CKD (glomerular filtration rate \<30mL/min/m2) and suspicion of pulmonary embolus, but can not be utilized if pulmonary parenchyma contains interstitial edema or alveolar occlusion due to pneumonia. If diagnostic tools for pulmonary embolus are not available, patients are subject to the risk of empiric treatment to avoid life-threatening complications of untreated pulmonary embolus. For those patients with CKD that undergo CT angiography, they are placed at risk of initiating dialysis. If this occurs multiple financial costs are associated with dialysis catheter placement and acute hemodialysis. If a patient instead is evaluated with gadolinium-based contrast modalities, there is the risk of nephrogenic systemic fibrosis and the morbidity associated with this iatrogenic disease process.

Ferumoxytol-enhanced MRI could avoid the risk of iodinated contrast and gadolinium contrast and accelerate the diagnosis and treatment of patients with pulmonary embolus.
Participants in the B-SWELL intervention will receive information about stress and goal setting in addition to healthy lifestyle behaviors. The intervention will take place weekly for eight weeks in groups of 11 to 13 midlife Black women for peer support. Outcome measures will include perceived general health, depressive symptoms, life's simple 7 (LS7) score, and number of unhealthy days. Data collections will occur at baseline, 8 weeks, and 12 weeks.
Before isoniazid preventive therapy is initiated, bacteriologically positive or radiographically progressive tuberculosis must be excluded. Appropriate evaluations should be performed if extra pulmonary tuberculosis is suspected.

Adults over 30 kg: 300 mg per day in a single dose.

Infants and Children: 10 mg/kg (up to 300 mg daily) in a single dose. In situations where adherence with daily preventative therapy cannot be assured, 20 mg/kg to 30 mg/kg (not to exceed 900 mg) twice weekly under the direct observation of a health care worker at the time of administration8.

Continuous administration of isoniazid for a sufficient period is an essential part of the regimen because relapse rates are higher if chemotherapy is stopped prematurely. In the treatment of tuberculosis, resistant organisms may multiply and the emergence of resistant organisms during the treatment may necessitate a change in the regimen.

For following patient compliance: the Potts-Cozart test9, a simple colorimetric6 method of checking for isoniazid in the urine, is a useful tool for assuring patient compliance, which is essential for effective tuberculosis control. Additionally, isoniazid test strips are also available to check patient compliance.

Concomitant administration of pyridoxine (B6) is recommended in the malnourished and in those predisposed to neuropathy (e.g., alcoholics and diabetics).
The invention discloses liquid medicine for curing the injuries of the muscle and tendon, which mainly consists of 56 Chinese herbal medicine including copperleaf herb, scandent schefflera stem and leaf, and asiatic toddalia root, and so on. The invention adopts liquor as carrier and has the effects of alleviating rheumatism, activating collaterals, relieving swelling and pain, activating blood and promoting poroma growth. The invention is mainly used for curing the injuries of the muscle and tendon. Proved by clinical experiments for years of the inventor, the liquid medicine has advantages of quick acesodyne, quick detumescence and fast poroma growth, etc.; the invention is especially suitable for curing the injuries of the muscle and tendon which can usually be cured within 3 to 5 days. Besides, the materials can be easily obtained, with low price but remarkable effect; moreover, the medical slag can be utilized as renewable resource, with fairly high economic benefits.
The invention relates to a nanometer type natural biological protein bee products and manufacturing method thereof. It adopts the nanometer biological technology structure process, extracts and utilizes the pharmacody properties of the drug in the largest extent and optimize combines the supercritical extracted and purified biological active effective constituent. It has micro molecule effects for control releasing and targeting, and has duplex functions of healthy care and diet therapy for inhibiting the brain atrophy, high blood fat and diabetes. It provides a novel protection and treatment measures for lowering the blood sugar and blood fat, reversing the canceration. The invention comprises following constituents: propolis 5-50b, royal jelly 10-45b, bee pollen 15-40b, ganoderma lucidum 8-25b, gingko leaf 10-20b, aloe 8-25b, nervonic acid 4-15b, chitosan 4-10b, maple leaf 4-10b, honey suckle 10-15b, licorice 8-15b, hawthorn fruit 8-15b.(b is a weight unit)
As with other iodinated contrast agents, the use of ULTRAVIST injection may obscure some lesions which were seen on non-contrast CT scans. Calcified lesions are less likely to enhance. The enhancement of tumors after therapy may decrease. The opacification of the inferior vermis following contrast agent administration has resulted in false-positive diagnosis. Cerebral infarctions of recent onset may be better visualized with contrast enhancement. However, older infarctions may be obscured by the contrast agent. 

In patients with normal blood-brain barriers and renal failure, iodinated contrast agents have been associated with blood-brain barrier disruption and accumulation of contrast in the brain. Accumulation of contrast in the brain also occurs in patients where the blood-brain barrier is known or suspected to be disrupted.
BACKGROUND AND AIMS: Self-management skills improve outcomes for patients with cirrhosis. While education programs exist to teach these skills, there are limited patient assessments to evaluate their efficacy. We aimed to develop and evaluate cirrhosis knowledge assessments for patients with compensated and decompensated cirrhosis.
METHODS: Across two institutions, a 4-stage process was undertaken: first, we developed a comprehensive set of questions regarding cirrhosis self-management. Second, the questions underwent critical review by patients and hepatology providers. Third, patients with cirrhosis answered these questions before and after a written educational tool. Questions were updated based on results. Fourth, patients answered the updated questions before and after a video educational tool. Binomial test or paired sample t-test was used to compare pre- and post-tests depending on question type.
RESULTS: In phase 3, 134 patients completed pre- and post-tests. 44% were decompensated, 81% were diagnosed with cirrhosis at least 3 years, and 52% were 60-75 years. 95% of single-answer questions were answered correctly by at least 70% of patients in the pre-test. None of the answers improved significantly with education. After phase 3, 6 questions were removed and 6 questions were edited to increase challenge. In phase 4, 96 patients (42 compensated, 54 decompensated) completed pre- and post-tests. In the compensated assessment, 3 questions improved after education and the summative score increased (7.9 to 9.0, P < 0.001). In the decompensated assessment, 4 questions improved after education and the summative score increased (7.0 to 7.7, P = 0.004).
CONCLUSION: Through a rigorous process, we created and evaluated cirrhosis knowledge assessments for patients with compensated and decompensated cirrhosis. Further validation is required and then these assessments can be used to improve patient education.
Primary caregivers of eligible PLWDS enrolled at PACE sites randomized to the intervention arm will be recruited by "module-trained COPE clinicians." After initial recruitment, the study team will carry out consent and screening procedures with caregivers and collect caregiver outcome data at baseline (before meeting with COPE clinicians) and follow-up (4 months post-implementation). Caregivers must complete a minimal dose of 4 sessions out of 10 to be included in follow-up measures. Outcomes will be reviewed for change from baseline to follow-up and compared to "caregivers receiving COPE from instructor-trained COPE clinicians" for non-inferiority.
The Promotora-led Intervention consists of a core curriculum or 12 group sessions of 90 minute duration over a 12-week period and will be followed by a maintenance phase of 10 biweekly and then monthly 90-minute sessions during months 4 through 12. One promotora will lead each session in Spanish, exploring such topics as being active, low-fat diets, portion control, self monitoring, problem solving and life-style changes.
During treatment period I participants received 120 μg per day desmopressin oral lyophilisate tablet for 14 days. Participants for whom treatment was effective (a reduction of ≥ 75% from Baseline in the number of wet nights), and who showed no problems with tolerability, continued to receive the same treatment for a further 14 days in treatment period II. Participants for whom efficacy was inadequate (a reduction of \<75% from Baseline in the number of wet nights), but who showed no tolerability problems, received an increased dose of desmopressin oral lyophilisate tablet 240 µg for 14 days in treatment period II.
To provide a basis for the functional expression of a curcumin derivative to attempt to use the derivative.SOLUTION: An antidiabetic composition contains a deketene derivative of a curcumin compound as an active ingredient. Further, a composition for improving insulin resistance contains a deketene derivative of a curcumin compound as an active ingredient. Further, a DPP-4 activity inhibitory composition contains a deketene derivative of a curcumin compound as an active ingredient. Further, a fat droplets formation inhibitory composition contains a deketene derivative of a curcumin compound as an active ingredient. Further, a composition for suppressing inflammatory cytokine production by precursor fat cells contains a deketene derivative of a curcumin compound as an active ingredient. The above compositions may be for normalizing a blood glucose level.SELECTED DRAWING: None
The process consists of (a) triturating and milling the vegetable raw material, e.g. immature dry fruit or citrus peel, opt. dehydrated, to a particle size of 2-3mm (b) mixing this with quicklime or slaked lime (c) extracting in reactors filled with water at pH 11-12 for minimum time, without forming gels or colloids (d) filtering in a press to obtain an alkaline filtrate (e) neutralising with agitation to pH 2-5 with dil. HCl or H2SO4, at 20-30 deg.C over 30 mins. (f) decanting the liquid for 3 h., until the hesperidin crystallises out (g) drawing off the mother liquor and collecting the crystalline ppt. in wash reactors (h) pressing the ppt. to reduce the water content to 50% and (i) drying in tray drying chambers by hot air at 100 deg.C to obtain hesperidin of over 97% purity by spectro-photometry.
PURPOSE:A bath agent, obtained by incorporating a main agent consisting of SHOCHU (low-class distilled spirit) with an adjuvant for promoting health, and useful for the health. CONSTITUTION:A bath agent for health, obtained by incorporating SHOCHU (low-class distilled spirit) having a high alcohol proof as a main agent with an adjuvant, and used by mixing with hot water in a bathtub in bathing. The above-mentioned bath agent is capable of improving the blood circulation very well, enhancing warming effect on the body and acting synergistically on promotion of the blood circulation due to the adjuvant, e.g. a substance contained in a hot spring, incorporated with the above-mentioned main agent. Furthermore, the bath agent produces effect on dermatopathy, neuralgia and chronic rheumarthritis by the action of individual sulfur in the adjuvant. EFFECT:Since the very inexpensive SHOCHU (low-class distilled spirit) having a high alcohol proof is contained as the main agent, the bath agent for health having improved effect on promotion of the blood circulation is obtained at a low cost.
Alkylphosphocholine analogs incorporating a chelating moiety that is chelated to gadolinium are disclosed herein. The alkylphophocholine analogs are compounds having the formula:or a salt therof. R1 includes a chelating agent that is chelated to a gadolinium atom; a is 0 or 1; n is an integer from 12 to 30; m is 0 or 1; Y is —H, —OH, —COOH, —COOX, —OCOX, or —OX, wherein X is an alkyl or an arylalkyl; R2 is —N+H3, —N+H2Z, —N+HZ2, or —N+Z3, wherein each Z is independently an alkyl or an aroalkyl; and b is 1 or 2. The compounds can be used to detect solid tumors or to treat solid tumors. In detection/imaging applications, the gadolinium emits signals that are detectable using magnetic resonance imaging. In therapeutic treatment, the gadolinium emits tumor-targeting charged particles when exposed to epithermal neutrons.
Individuals with substance use disorders (SUDs) can be readily identified within primary care settings, but current interventions are not effective at linking them to SUD treatment. Patient and system level barriers present significant challenges and new, more robust, linkage models are needed that can successfully overcome the barriers. Identifying more effective linkage models is a priority within addiction health services, since untreated individuals with SUDs have poorer health and employment outcomes over time as well as use significantly more acute care services, resulting in substantially higher medical costs, compared with those who receive SUD treatment.

Results from three clinical trials conducted by the applicant team have demonstrated the effectiveness of Recovery Management Checkups (RMC) as a linkage model for individuals needing SUD treatment. Moreover, RMC participants were significantly more likely to enter treatment, enter sooner, and stay longer, having fewer days of use and fewer SUD symptoms. Outcomes were also associated with lower health care utilization, decreased criminal activity, and substantial savings to society, thereby offsetting the costs of additional treatment. RMC was modified for primary care (RMC-PC) and pilot results conducted in Federally Qualified Health Centers (FQHCs) indicated RMC-PC significantly increased the number of patients who agreed to go to treatment (72% vs. 97%; OR=12.6, p\<.05) and who showed for treatment (12% vs. 75%, OR=22.0, p\<.0001). Moreover, relative to patients in these same settings who received the usual referral condition, those who received RMC-PC had significantly greater reductions (post-pre) in their past-month days of any illicit drug use or misuse of prescription medications (-11.21 vs -22.11 days, d=-0.81, p\<.001).

In this trial, investigators will: a) recruit 300 adult patients with SUD through SBIRT programs in 4 FQHC sites, b) randomly assign half to a referral as usual control and half to RMC-PC, and c) conduct quarterly follow-ups for 12-months post enrollment. Hypotheses include: H1 Relative to the control patients, patients receiving RMC-PC will be more likely to: a) initiate SUD treatment sooner, b) receive any SUD treatment, and c) receive more days of SUD treatment. H2. Relative to the control patients, patients receiving RMC-PC and those who receive more SUD treatment will report fewer days of: a) any alcohol use, b) use of illicit drugs or misuse of prescription medications, c) any substance use, and d) SUD problems. H3. The days of treatment will mediate the relationship between RMC-PC and changes in the pre and post measures of the dependent variables in H2.
FIELD: medicine, diet therapy. SUBSTANCE: patient is suggested uniform diet during the time necessary for body readaptation including training and activation stages. Body state values are registered according to every stage. Individual approbation of different foodstuffs is conducted followed by evaluation of patient's response peculiarities. At activation stage substances are additionally injected that enable to induce readaptation at individual dosage to provide optimal degree of readaptation intensity. EFFECT: higher efficiency in choosing foodstuffs. 2 cl
A tablet with differentiated oromucosal and enteric absorption comprises glutathione and/or its acetyl or proprionyl form; micro-granules each formed of an inner core of L-cysteine and/or its dimer L-Cystine, and an outer gastro-resistant coating consisting of a lipophilic matrix. The glutathione and/or its acetyl or proprionyl form may be present in the range of about 15% to about 30% w/w by weight of the tablet, and the L-cysteine and/or its dimer L-Cystine may be present in the range of about 1% to about 10% w/w by weight of the tablet. The tablet may comprise one or more surfactants, particularly those having a hydrophilic-lipophilic balance between 10 and 20, such surfactants can be selected from polysorbates, poloxamers, polyethylene glycol, di- and triethanolamine, glyceryl monosterate, soya lectin or sucrose esters. The gastro-resistant coating may be formed of hydrogenated vegetable fats, such as mono-, di- or triglyceride behanates, glyceryl palmitostearate, polyethylene glycol esters, particularly those wherein the hydrogenated vegetable fats have a melting point between 30Â°C and 100Â°C. The micro-granules can have a particle size of between 250 and 3000 microns. The tablet may further include nutritional supplements, such as vitamin C or selenium.
The invention provides a composition for preventing and treating stretch marks, which comprises the following raw materials: the mannose aldehydic ester silanol and the transdermal component are acetyl chitosamine and ectoine. The mass ratio of the mannitol ester silanol to the transdermal component is (4-40) to (2-51). The mass ratio of the usage amount of the acetyl chitosamine to the usage amount of the ectoine is (3-5) to (1-3). The composition is a topical composition, and can be made into water, milk, cream, essence, gel, peritoneum, etc. The composition for preventing and treating striae gravidarum, which is provided by the invention, contains the acetyl chitosamine and the ectoine, can effectively improve the transdermal absorption rate of the mannose aldehyde ester silanol, and has a synergistic effect, so that striae gravidarum can be prevented and improved in an all-round way, and meanwhile, the composition has no stimulation to a human body, is safe and has no toxic or side effect. The composition has simple component types, is easy to prepare, and is easy to be mixed with other components into cosmetics.